Epidemiological and antimicrobial resistance profile of catheter-associated and non-catheter urinary tract infections in trauma patients (2017–2024) Authors: Parul Singh, M Nizam Ahmed, Arpan Kumar Thakur, Ashish Kumar Srivastava, Mamta Puraswani, Bharat Chandra Das, Madhavi Kirti, Vanlal Tluanpuii, Rasna Parveen, Kumari Vandana Singh, Subodh Kumar, Sushma Sagar, Kapil Dev Soni, Richa Aggarwal, Ashish Bindra, Keshav Goyal, Gyanendra Pal Singh, Navdeep Sokhal, Kamran Farooque, Purva Mathur Published: 2025 ABSTRACT AbstractBackgroundCatheter-associated urinary tract infections (CAUTIs) are a major healthcare-associated infection (HAI) in trauma care settings, contributing to morbidity, mortality and antimicrobial resistance. In this study we characterize the epidemiology, microbiological profile, antimicrobial resistance patterns, and clinical outcomes of CAUTIs and non-CAUTI urinary tract infections (UTIs) at a Level 1 Trauma Centre in India from 2017 to 2024, using a modified CDC-NHSN definition and digital surveillance.MethodsA retrospective analysis of 723 UTI events was conducted using Centers for Disease Control and Prevention’s National Healthcare Safety Network (CDC-NHSN) definitions, modified to include Candida spp. at ≥ 105 CFU/mL. Surveillance was performed by dedicated Hospital Infection Control Nurses (HICNs) using a digital system. Microbiological identification and antimicrobial susceptibility testing (AST) were conducted via the conventional manual methods and automated systems.Resultsof 723 UTI events, 608 (84.0%) were CAUTIs. The cohort had a median age of 34 years (IQR:22–45) and was 76% male. Pseudomonas aeruginosa (18%), Klebsiella pneumoniae (17.9%), and Escherichia coli (15%) were predominant pathogens. Antimicrobial resistance was high, with 100% resistance to ceftazidime in Acinetobacter baumannii and 93.6–94.1% resistance to ciprofloxacin in Klebsiella spp. and Enterococcus spp. Mortality was 25.5% (28.2% in CAUTI, 12.9% in non-CAUTI).ConclusionThis large-scale, trauma specific study with modified fungal criteria and digital surveillance highlights the importance of CAUTI burden and the high resistance in pathogens causing this infection.Clinical trial numberNot applicable.Keywords: Trauma care, UTI, Antimicrobial resistance, CAUTI, Digital surviellance Introduction Catheter-associated urinary tract infections (CAUTIs) are a leading cause of healthcare-associated infections (HAIs), particularly in trauma care and intensive care unit (ICU) settings where indwelling urinary catheters are frequently used [1, 2]. These infections contribute to prolonged hospital stays, increased healthcare costs, morbidity, and mortality, with global incidence rates of 1.7–3.2 per 1000 catheter-days [3, 4]. The rise of antimicrobial resistance, especially among Gram-negative bacteria and emerging fungal pathogens, poses significant challenges, particularly in resource-constrained environments [5–7]. Trauma centers face unique pressures due to high patient volumes, complex injuries, and limited infection control infrastructure, amplifying the CAUTI burden [8–10]. Recent studies have documented regional variations in CAUTI epidemiology, with Gram-negative pathogens like Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli predominating in Asian and Indian settings [11, 12]. A recent study highlighted the growing threat of multidrug-resistant (MDR) and extensively drug-resistant (XDR) organisms, alongside fungal pathogens such as Candida auris, emphasizing the need for enhanced surveillance [5]. Another study noted shifts in HAI patterns during the COVID-19 pandemic, with changes in pathogen distribution and resistance profiles [13]. However, longitudinal studies using standardized, digitally supported surveillance and modified definitions to capture fungal CAUTIs remain scarce. This study addresses these gaps by analyzing 723 UTI events from May 2017 to April 2024 at a Level-1 Trauma Center in India, employing a modified CDC-NHSN definition that includes Candida spp. at ≥ 10⁵ CFU/mL to enhance fungal detection along with clinical systems with UTI [14]. We provide a large-scale, trauma-specific dataset with detailed microbiological, resistance, and outcome data. Methodology The study was conducted at a Level-1 Trauma Center in India, receiving patients from across the country. This centre is part of a large tertiary care, academic hospital with a capacity of 2,500 beds. The Trauma Centre comprises 284 beds, including 32 beds in the intensive care unit (ICU) and 30 beds in a high-dependency unit (HDU) designated for polytrauma patients. Infection surveillance activities are supported by a dedicated team consisting of ten full-time Hospital Infection Control Nurses (HICNs) and one data entry operator assigned exclusively for surveillance documentation. Healthcare-associated infections (HAIs) were identified based on the most recent definitions provided by the Centers for Disease Control and Prevention’s National Healthcare Safety Network (CDC-NHSN). A slight modification was made to the urinary tract infection (UTI) definition, isolation of at least one organism growing at ≥ 10⁵ CFU/mL which included Candida spp. (NHSN excludes Candida, Moulds, and dimorphic fungi in UTI case definition) along with clinical symptoms of UTI [14]. All surveillance definitions and updates were implemented in real-time. Surveillance for CAUTIs was initiated in patients who remained in the intensive care unit (ICU) for more than two consecutive calendar days. A standardized proforma was used to document vital signs, relevant clinical parameters, and catheter-related information for each ICU patient, including the dates of catheter insertion, replacement, and removal. These records were subsequently transferred to the microbiology department, where the data was systematically entered on a digital platform HAIS India (www.haisindia.com). All clinical specimens for diagnosis were collected by the treating physicians based on clinical judgment and predefined diagnostic criteria. Microbiological processing of the samples was carried out following standard laboratory methods [15]. Microorganism identification was performed using the automated systems (Vitek-MS (BioMérieux, Marcy-l’Etoile, France) and antimicrobial susceptibility testing (AST) was conducted according to the latest CLSI guidelines. manufacturer’s guidelines. Results Cohort demographics and clinical characteristics A retrospective analysis of 723 urinary tract infection (UTI) events included 608 catheter-associated urinary tract infections (CAUTI) and 115 non-CAUTI cases. The cohort had a median age of 34 years (interquartile range: 22–45), with 76% males (72.7% in CAUTI, 93.9% in non-CAUTI). Median duration of stay in the unit was 34 days (interquartile range: 20–64) for CAUTI and 27 days (interquartile range: 15–57) for non-CAUTI cases. Median time from admission to outcome was 7 days (interquartile range: 4–14) for CAUTI and 8 days (interquartile range: 5–12) for non-CAUTI cases. The demographic and clinical characteristics are summarized in Table 1. Table 1Cohort demographics and clinical characteristicsCharacteristicOverall (N = 723)CAUTI (N = 608)Non-CAUTI (N = 115)Male, n (%)550 (76.0)442 (72.7)108 (93.9)Age, median (IQR), years34 (22–45)34 (22–45)32 (22–45)Duration of Stay, median (IQR), days33 (19–63)34 (20–64)27 (15–57)Time to Outcome, median (IQR), days7 (4–13)7 (4–14)8 (5–12) Cohort demographics and clinical characteristics Temporal distribution of CAUTI and Non-CAUTI cases Across the study period (2017–2024), CAUTI constituted the majority of reported events (4.6 per 1,000 urinary catheter days); however, their proportional representation declined over time. In the pre-COVID era (2017–2020), CAUTIs accounted for 87.8% (5.3 per 1,000 urinary catheter days, Device utilization ratio 0.47) of cases, whereas in the post-COVID period (2021–2024), this declined to 76.7% (3.9 per 1,000 urinary catheter days, Device utilization ratio 0.37). A corresponding increase in non-CAUTI events was observed, This Temporal distribution is presented in Table 2. Table 2Temporal distribution of CAUTI and Non-CAUTI casesYear/PeriodTotal Events, nCAUTI, n (%)Non-CAUTI, n (%)2017–188679 (91.9)7 (8.1)2018–19199176 (88.4)23 (11.6)2019–20189161 (85.2)28 (14.8)2020–2144 (100)0 (0)2021–222018 (90.0)2 (10.0)2022–239979 (79.8)20 (20.2)2023–2412691 (72.2)35 (27.8) Temporal distribution of CAUTI and Non-CAUTI cases Microbiological profile A total of 782 isolates were identified, which included Pseudomonas aeruginosa 141 (18%), Klebsiella pneumoniae 140 (18%), and Escherichia coli 117 (15%) being the most commonly isolated organisms overall. Higher proportion of Acinetobacter baumannii and Proteus mirabilis observed. Fungal pathogens such as Candida spp. were notably more frequent in CAUTI cases 78 (12%) than in non-CAUTI cases 5 (4%), particularly Candida tropicalis. Rare isolates including Candida auris, Stenotrophomonas maltophilia, and Trichosporon asahii were observed in small numbers as shown in Table 3. Table 3Pathogen distribution by CAUTI and Non-CAUTI statusPathogen GroupOrganismOverall,n (%)782CAUTI,n (%)656Non-CAUTI,n (%)126Gram-Negative Enterobacteriaceae Klebsiella pneumoniae 140 (17.9)115 (17.5)25 (19.8) Escherichia coli 117 (15.0)97 (14.8)20 (15.9) Proteus mirabilis 25 (3.2)20 (3.0)5 (4.0) Providencia rettgeri 25 (3.2)21 (3.2)4 (3.2) Providencia stuartii 16 (2.0)12 (1.8)4 (3.2) Enterobacter cloacae 13 (1.7)9 (1.4)4 (3.2)Gram-NegativeNon-Enterobacteriaceae Pseudomonas aeruginosa 141 (18.0)111 (16.9)30 (23.8) Acinetobacter baumannii 57 (7.3)45 (5.8)12 (1.5)Gram-Positive Enterococcus faecium 43 (5.5)37 (5.6)6 (4.8)FungalCandida spp.83 (10.6)78 (11.9)5 (4.0) Candida tropicalis 59 (7.5)54 (8.2)5 (4.0) Candida albicans 15 (1.9)14 (2.1)1 (0.8) Pathogen distribution by CAUTI and Non-CAUTI status Gram-Negative Non-Enterobacteriaceae Time to infection and length of stay Time to infection (TTI) included 370 cases developing in ≤ 7 days, 186 cases in 8–14 days, 88 cases in 15–21 days, and 79 cases in > 21 days. Length of stay (LOS) included 7 cases having LOS ≤ 7 days, 112 cases had 8–14 days, 101 cases had 15–21 days, and 503 cases had > 21 days. Detailed distribution of TTI and LOS are presented in Table 4. Table 4Time to infection and length of stay by CAUTI and Non-CAUTI statusMetricCategoryOverall, n (%)723CAUTI, n (%)608Non-CAUTI, n (%)115Time to Infection (days)≤ 7370 (51.2)314 (84.9)56 (15.1)8–14186 (25.7)154 (82.8)32 (17.2)15–2188 (12.2)78 (88.6)10 (11.4)> 2179 (10.9)62 (78.5)17 (21.5)Length of Stay (days)≤ 77 (1.0)5 (71.4)2 (28.6)8–14112 (15.5)89 (79.5)23 (20.5)15–21101 (14.0)82 (81.2)19 (18.8)> 21503 (69.6)432 (85.9)71 (14.1) Time to infection and length of stay by CAUTI and Non-CAUTI status The Final outcomes included 481 cases (71.7%) who were discharged (393 CAUTI, 70.2%; 88 non-CAUTI, 87.1%), 171 cases (25.5%) who died (158 CAUTI, 28.2%; 13 non-CAUTI, 12.9%). Outcomes: 14 days outcome & final outcomes is tabulated in Table 5. Table 5Clinical outcomes by CAUTI and Non-CAUTI statusOutcomeCategoryOverall, n (%)723CAUTI, n (%)608Non-CAUTI, n (%)11514-Day OutcomeDied90 (12.4)79 (13.0)11 (9.6)Discharged182 (25.2)138 (22.7)44 (38.2)Other*451 (62.4)391 (64.3)60 (52.2)Final OutcomeDied171 (25.5)158 (26.0)13 (11.3)Discharged481 (71.7)393 (64.6)88 (76.5)Other*71 (10.6)57 (9.4)14 (12.2)* Transferred to another hospital Left against medical advice Clinical outcomes by CAUTI and Non-CAUTI status * Transferred to another hospital Left against medical advice Antimicrobial resistance patterns Antimicrobial resistance patterns for Acinetobacter baumannii (n = 57) showed 100% resistance to ceftazidime (56/56), 97.3% to cefepime (36/37), and 98.2% to ciprofloxacin (54/55), with 100% susceptibility to colistin (25/25) and 62.2% to minocycline (28/45). Escherichia coli (n = 117) had 100% resistance to ampicillin (63/63) and cefazolin (20/20), with 98.2% susceptibility to colistin (55/56) and 50.6% to ertapenem (42/83). Klebsiella spp. (n = 142) showed 93.6% resistance to ciprofloxacin (132/141) and 94.4% to cefepime (101/107), with 82.5% susceptibility to colistin (52/63). Pseudomonas spp. (n = 146) had 100% resistance to minocycline (9/9) and 89.0% to ciprofloxacin (129/145), with 98.5% susceptibility to colistin (66/67). Enterococcus spp. (n = 52) showed 97.5% resistance to erythromycin (39/40) and 94.1% to ciprofloxacin (48/51), with 93.8% susceptibility to linezolid (45/48) and 73.5% to vancomycin (36/49). Candida spp. (n = 169) showed 97.8% susceptibility to voriconazole (90/92), 94.7% to micafungin (90/95), and 89.9% to fluconazole (89/99), with resistance rates of 2.2%, 5.3%, and 10.0%, respectively as shown in Table 6. Table 6Antimicrobial resistance patterns of number (%) of common urinary pathogensPathogen GroupOrganismAntibiotic/AntifungalResistance, n/N (%)Susceptibility, n/N (%)Gram-Negative Enterobacteriaceae Escherichia coli Ampicillin63/63 (100)0/63 (0)Colistin1/56 (1.8)55/56 (98.2) Klebsiella spp.Ciprofloxacin132/141(93.6)9/141 (6.4)Colistin11/63 (17.5)52/63 (82.5)Gram-NegativeNon-Enterobacteriaceae Acinetobacter baumannii Ceftazidime56/56 (100)0/56 (0)Colistin0/25 (0)25/25 (100) Pseudomonas spp.Ciprofloxacin129/145 (89.0)16/145 (11.0)Colistin1/67 (1.5)66/67 (98.5)Gram-Positive Enterococcus spp.Ciprofloxacin48/51 (94.1)3/51 (5.9)Linezolid3/48 (6.3)45/48 (93.8)Fungal Candida spp.Voriconazole2/92 (2.2)90/92 (97.8)Fluconazole10/99 (10.0)89/99 (89.9) Antimicrobial resistance patterns of number (%) of common urinary pathogens Klebsiella spp. Gram-Negative Non-Enterobacteriaceae Pseudomonas spp. Enterococcus spp. Candida spp. Discussion This study provides a comprehensive analysis of catheter-associated urinary tract infections (CAUTIs) and non-CAUTI analysed 723 UTI events. The high CAUTI burden, distinct microbiological profiles, and alarming antimicrobial resistance patterns align with global trends, offering a replicable model for HAI monitoring in resource-limited settings [1, 2, 5]. CAUTI burden and temporal trends The predominance of CAUTIs (84.1% of 723 UTI events) aligns with findings from high-risk settings. Recent studies reported CAUTI incidence rates of 1.7–3.2 per 1000 catheter-days across 235 ICUs in eight Asian countries, highlighting the challenge in resource-constrained settings [3, 4]. A recent study documented a sustained CAUTI burden over a decade at another Indian trauma center, with rates comparable to our CAUTI events [8]. Our unique temporal analysis across pre-COVID (87.8% CAUTI), COVID (100% CAUTI), and post-COVID (76.7% CAUTI) periods reveals a decline in CAUTI proportion post-COVID, mirroring a recent study that noted shifts in HAI patterns due to altered patient demographics and enhanced infection control during the pandemic [13]. The digital system and daily HICN surveillance ensured accurate data capture, surpassing the scope of manual or shorter-term surveillance in similar studies [8, 9]. Microbiological profile and regional comparisons Pseudomonas aeruginosa (18.0%), Klebsiella pneumoniae (17.9%), and Escherichia coli (15.0%), predominantly reflects patterns in recent studies from India and globally [8, 11, 12]. A recent study reported E. coli as a leading cause of community-acquired UTIs in India, with increasing resistance during the COVID-19 period [11], while another identified Gram-negative dominance in CAUTIs at a trauma center [8]. Our modified CDC-NHSN definition, including Candida spp. at ≥ 10⁵ CFU/mL, enhanced detection of fungal CAUTIs (10.6% overall, 11.9% in CAUTI), particularly Candida tropicalis (7.5%), addressing a gap noted in a recent study on emerging fungal pathogens like Candida auris [5]. The higher prevalence of P. aeruginosa in non-CAUTI cases (23.8% vs. 16.9% in CAUTI) aligns with a recent study reporting non-fermenters in non-CAUTI settings [2]. The VITEK-2 system ensured standardized microbial identification and AST, corroborating a recent study on MDR pathogens in Indian ICUs [7]. Antimicrobial resistance patterns The high antimicrobial resistance rates underscore the global crisis in trauma settings. Acinetobacter baumannii exhibited 100% resistance to ceftazidime and 98.2% to ciprofloxacin, consistent with a recent study on MDR Acinetobacter spp. in Indian ICUs [7]. E. coli and Klebsiella spp. showed near universal resistance to ampicillin (100%) and ciprofloxacin (93.6–94.1%), consistent with findings reported in recent literature from inpatient and community healthcare settings [1, 11]. Candida spp. showed favourable susceptibility to voriconazole (97.8%) and micafungin (94.7%), consistent with a recent study on C. auris [5], but 10.0% fluconazole resistance suggests cautious antifungal stewardship, as noted in a recent study on catheter technologies [10]. Clinical outcomes and risk factors The 25.5% mortality rate (28.2% in CAUTI, 12.9% in non-CAUTI) exceeds that reported in a recent study on elderly CAUTI patients (14.7%), likely due to trauma severity [16]. Prolonged LOS (69.6% >21 days) and early TTI (51.2% ≤7 days) in CAUTI cases align with a recent study identifying prolonged catheterization as a risk factor [6]. Extended monitoring post-ICU discharge enhanced outcome accuracy. Higher discharge rates in non-CAUTI cases (87.1% vs. 70.2% in CAUTI) reflect less severe courses, consistent with a recent study [17]. Male predominance (76.0%, 93.9% in non-CAUTI) reflects trauma center demographics, as noted in a recent study [12]. Implications for infection control Our findings support targeted CAUTI prevention, as advocated in a recent study on catheter removal protocols [18]. High resistance rates necessitate susceptibility-guided therapy, as recommended in a recent study. Conclusion This study’s large-scale, trauma-specific analysis with modified fungal criteria and digital surveillance highlights the CAUTI burden and resistance patterns. It offers a replicable model for HAI monitoring, addressing gaps in fungal detection and longitudinal data, and supports enhanced infection control and stewardship in resource-limited settings. Acknowledgements I am thankful to all my research, lab staff and data entry operators for all the help and support. Abbreviations Catheter-associated urinary tract infections Healthcare-associated infection Urinary tract infections Centre for Disease Control and Prevention’s National Healthcare Safety Network Hospital Infection Control Nurses Multidrug-resistant Intensive care unit Antimicrobial Susceptibility Testing Author contributions PS, MNA and PM wrote the main manuscript text. AKT, AKS, MP, MK, BCD, VT, RP, KVS assisted in data collection, laboratory investigation, data analysis. All authors reviewed the manuscript. Funding Not applicable. Data availability Data is provided within the manuscript. Declarations Ethics approval The study protocol received approval from the Institutional Ethics Committee AIIMS, New Delhi (IEC 633/03-09-2021) Our study adhered to the Declaration of Helsinki. The Institutional Ethics Committee AIIMS, New Delhi has agreed to waive the consent of the participants. Consent to participate Nor applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Citations Data Availability Statement Data is provided within the manuscript.